MAGE family member A4Genealiases: CT1.4 · MAGE-41 · MAGE-X2 · MAGE4 · MAGE4A · MAGE4B
Q-omics provides the consensus-scored MAGEA4 profile across patient tissues and cancer cell-line models. MAGEA4 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MAGEA4 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, MAGEA4 RNA expression shows 10,526 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, HNSC, and TGCT as cancer lineages where MAGEA4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGEA4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGEA4 survival associations across molecular data types. MAGEA4 RNA expression shows survival associations in the most cancer types (14), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGEA4 RNA expression–survival associations across cancer types. High MAGEA4 expression shows unfavorable associations in KIRC, BRCA, LIHC, UCEC and MESO, but favorable associations in ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MAGEA4 RNA expression.
This table summarizes MAGEA4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MAGEA4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGEA4 shows lower tumor expression in PRAD and higher tumor expression in HNSC, LUSC, BLCA, BRCA and STAD. The HNSC box plot shows higher MAGEA4 RNA expression in tumor versus normal tissue (log2 FC = +2.798, t-test p < 0.001).
This table shows molecular features associated with MAGEA4 in patient tissues and cancer cell lines. In patient samples, MAGEA4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGEA4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Myeloma.
